Gilead Sciences Inc. closed $6.85 short of its 52-week high ($98.90), which the company achieved on November 11th.

The CHMP recommends the approval of Gilead's seladelpar in combination with ursodeoxycholic acid for the treatment of primary ...

Roche RHHBY announced that the European Medicines Agency has approved a prefilled syringe (PFS) of the ophthalmology drug ...

Gilead Sciences, Inc. (GILD) stock saw a decline, ending the day at $91.86 which represents a decrease of $-0.52 or -0.56% from the prior close of $92.38. The stock opened at $91.66 and touched a low ...

Gilead (GILD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

New research revealed tumor mutational burden was linked to improved event-free survival with pembrolizumab in early TNBC, ...

Some 90% of investigational drugs fail—and success rates are even more dire in the neuro space. Here, BioSpace looks at five ...

Buying $100 In GILD: If an investor had bought $100 of GILD stock 20 years ago, it would be worth $1,075.53 today based on a ...

Pharmaceutical companies have an untapped potential to transform global health, but they cannot act alone. Governments, NGOs, ...

In a report released today, Joseph Catanzaro from Piper Sandler maintained a Buy rating on Repare Therapeutics (RPTX – Research Report), with a ...

UK-based NeoPhore Limited, a small molecule neoantigen immuno-oncology company, today announced the appointment of Michael ...

University of Utah Health announced Friday the development of a promising new HIV drug. The drug, lenacapavir, has been named ...